

For Immediate Release

December 13, 2018 Sawai Pharmaceutical Co., Ltd.

Sawai Launches Six Generic Drugs with 14 Strengths

Osaka, Japan – December 13, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of six compounds with 14 strengths of generic drugs. They will be launched sequentially beginning tomorrow. Sawai's product line now includes 310^{*} compounds with 756 strengths. Among the six compounds, four compounds, "Mirtazapine", "Atomoxetine Hydrochloride", "Tramadol Hydrochloride and Acetaminophen" and "Capecitabine", will be launched for the first time as generics.

- * TOARASET[®] Combination Tablets are Tramadol Hydrochloride and Acetaminophen, and are counted as one compound.
- * FREWELL® Combination Tablets are Norethisterone and Ethinylestradiol, and are counted as one compound.

The list of new products:

1. MIRTAZAPINE OD Tablets 15 mg [SAWAI] and 30 mg [SAWAI], MIRTAZAPINE Tablets 15 mg [SAWAI] and 30 mg [SAWAI]

ミルタ OD15 ザピン サワイ Generic name: Mirtazapine

Indications: Depression and depressive state
 Brand products: REFLEX® TABLETS 15 mg and 30 mg,

REMERON® Tablets 15 mg and 30 mg

• Striking features: Orally disintegrating (OD) tablets are the first dosage form for

Mirtazapine. Sawai aimed to improve patient convenience by developing OD tablets which are taken at bedtime without water. In addition, "Product name" and "Strength" are printed on the tablets, allowing the product to be identified even after removing

from blister packs.

2. ATOMOXETINE Capsules 5 mg [SAWAI], 10 mg [SAWAI], 25 mg [SAWAI] and 40 mg [SAWAI]

71- E = to 25mg

·Generic name: Atomoxetine Hydrochloride

•Indications: Attention-deficit and hyperactivity disorder (ADHD)
•Brand products: Strattera® Capsules 5mg, 10 mg, 25 mg and 40 mg

·Striking features: The capsules are miniaturized and are printed with the "Generic

name" and "Strength".

3. TOARASET® Combination Tablets [SAWAI]



•Generic name: Tramadol Hydrochloride and Acetaminophen

·Indications: Non-cancerous chronic pain and pain after tooth extraction that cannot be

managed by treatments with non-opioid analgesics

•Brand products: TRAMCET® Combination Tablets

Striking features: The "Product name" is printed on

both sides of tablet.

"Therapeutic category", "Product name" and "Generic name and Strength" are indicated on the

blister pack.





4. ROPINIROLE Extended-release Tablets 2 mg [SAWAI] and 8 mg [SAWAI]

•Generic name: Ropinirole Hydrochloride •Indications: Parkinson's disease

Brand products: ReQuip® CR Tablets 2 mg and 8 mg

5. FREWELL® Combination Tablets LD [SAWAI] and ULD [SAWAI]

SW-F ULD

·Generic name: Norethisterone and Ethinylestradiol

·Indications: Dysmenorrhea

•Brand products: LUNABELL® Tablets LD and ULD
•Striking features: The blister pack can be set to the

instruction card. And easy for disposal.



Instruction card

6. CAPECITABINE Tablets 300 mg [SAWAI]



Generic name: Capecitabine

Indications: Inoperable or recurrent breast cancer, colorectal cancer, gastric cancer

•Brand products: XELODA® Tablets 300

·Striking features: Sawai is launching the first generic of this product. Since


anti-cancer treatment can be lengthy, generic drugs play an


important role to help patients financially.

A special feature of packages:

Crushable packaging box







This box can be easily crushed upon disposal.

This feature applies to MIRTAZAPINE OD Tablets, MIRTAZAPINE Tablets, and TOARASET® Combination

Tablets.